Dilated Cardiomyopathy Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Pfizer, Capricor Therapeutics, MyoKardia, Cumberland Pharmaceuticals, Berlin Cures

DelveInsight's "Dilated Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dilated Cardiomyopathy, historical and forecasted epidemiology as well as the Dilated Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Discover which therapies are expected to grab the Dilated Cardiomyopathy Market Share @ Dilated Cardiomyopathy Market Outlook- https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Dilated Cardiomyopathy Market Report
• In February 2025, Cumberland Pharmaceuticals announced a phase 2 randomized, double-blind, placebo-controlled, multiple dose study with an optional open-label extension to determine the safety, pharmacokinetics (PK) and efficacy of two doses of oral ifetroban in subjects with DMD. DMD patients who meet the inclusion criteria and none of the exclusion criteria will receive oral ifetroban or placebo once daily for 12 months.
• In the 7MM, the total dilated cardiomyopathy prevalence were estimated to be approximately 3,045,174 in 2023, of which the US accounted for around 45%, while EU4 and the UK accounted for nearly 43%, and Japan accounted for approximately 12% of the total dilated cardiomyopathy prevalent cases. These cases are expected to increase by 2034.
• Among the 7MM, the US accounted for nearly 52% of the total diagnosed dilated cardiomyopathy prevalence. These cases are expected to increase during the study period (2020-2034).
• As per DelveInsight analysis, EU4 and the UK accounted for around 402,538 diagnosed prevalent cases of dilated cardiomyopathy in 2023. These cases are expected to change during the forecast period (2024-2034).
• Among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of dilated cardiomyopathy, accounting for nearly 103,096 cases, followed by France and the UK with approximately 83,529, and 83,410, respectively while Spain had the least cases i.e. around 57,806 in 2023.
• According to estimates based on DelveInsight's epidemiology model, dilated cardiomyopathy exhibits a higher male preponderance than females in the US. Of the total diagnosed prevalent cases in the US, nearly 63% were males and 37% were females, in 2023.
• In the US, there were nearly 194,036 cases due to family history or genetic causes, while other non-familial causes accounted for approximately 360,352 cases in 2023. As per the analysis, these cases are expected to increase by 2034.
• In 2023, among the 7MM, Japan had the second-highest cases of dilated cardiomyopathy, contributing approximately 11% to the total diagnosed prevalent cases of dilated cardiomyopathy.
• As per DelveInsight's estimates, in Japan, non-familial/other cases and genetic/familial cases of dilated cardiomyopathy accounted for 70% and 30% of the total diagnosed cases of dilated cardiomyopathy respectively in 2023, which are expected to increase by 2034.
• The leading Dilated Cardiomyopathy Companies such as Pfizer, Capricor Therapeutics, MyoKardia, Cumberland Pharmaceuticals, Berlin Cures, and others.
• Promising Dilated Cardiomyopathy Pipeline Therapies such as Danicamtiv, Ixmyelocel, ARRY-371797, Ifetroban, BC 007, and others.

Stay ahead in the Dilated Cardiomyopathy Market with DelveInsight's Strategic Report @ Dilated Cardiomyopathy Market Outlook- https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dilated Cardiomyopathy Epidemiology Segmentation in the 7MM
• Total Prevalence of Dilated Cardiomyopathy
• Prevalent Cases of Dilated Cardiomyopathy by severity
• Gender-specific Prevalence of Dilated Cardiomyopathy
• Diagnosed Cases of Episodic and Chronic Dilated Cardiomyopathy

Download the report to understand which factors are driving Dilated Cardiomyopathy Epidemiology trends @ Dilated Cardiomyopathy Prevalence- https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dilated Cardiomyopathy Marketed Drugs
• CORLANOR (ivabradine): Amgen/Les Laboratoires Servier
CORLANOR (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated for the new treatment of dilated cardiomyopathy symptomatic heart failure due to dilated cardiomyopathy in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate. Its mechanism of action involves the inhibition of the IF channels in the sinoatrial node of the heart.

Dilated Cardiomyopathy Emerging Drugs
• Danicamtiv (MYK-491): Bristol Myers Squibb
Danicamtiv (MYK-491) is an orally administered small molecule designed to increase the number of myosin-actin cross-bridges formed during cardiac muscle contraction while having minimal impact on diastolic function. In the heart, myosin is the motor protein that binds to actin to generate the force and movement of contraction. In patients with dilated cardiomyopathy and systolic heart failure, in which the left ventricle of the heart is too distended and weak to pump blood to meet the body's needs adequately, MYK-491 is intended to increase myosin-actin engagement, thereby targeting the biomechanical defects underlying disease and improving cardiac contractility.

• BC007: Berlin Cures
BC007 is a DNA aptamer-based compound that binds to and eliminates pathogenic autoantibodies directed against the beta-1 adrenoceptor, a receptor belonging to the large family of cell surface receptors known as G-protein coupled receptors (GPCR) that regulate the heart's rate and contraction strength. Administered via intravenous (IV) route, the drug candidate development is based on the APTACURES platform of GPCR-AAB-binding-aptamers.

To learn more about New Treatment of Dilated Cardiomyopathy Guidelines, visit @ Dilated Cardiomyopathy Treatment Market Landscape- https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dilated Cardiomyopathy Market Outlook
Currently, the New Treatment of Dilated Cardiomyopathy is mainly dependent on pharmacological therapy, pacing therapy, surgical options, and CORLANOR (ivabradine). The pharmacological therapies consist of diuretics, inotropic agents, afterload-reducing agents, beta-blockers, anticoagulation medications, and anti-arrhythmia medications. The main diuretics that are prescribed for the treatment are furosemide, spironolactone, bumetanide, and metolazone. Common side effects of diuretics include dehydration and abnormalities in the blood chemistry, particularly potassium loss.

Dilated Cardiomyopathy Drugs Market Insights
Dilated cardiomyopathy is characterized by the enlargement (dilation) of the heart's left ventricle, impairing its ability to pump blood efficiently. Some of the drug classes commonly used in the management of dilated cardiomyopathy include ACE inhibitors, angiotensin receptor blockers, beta-blockers, and others. Hyperpolarization-activated cyclic nucleotide-gated channels play a crucial role in the generation of pacemaker currents in the sinoatrial node of the heart. These channels, specifically contribute to the IF current, which regulates the spontaneous depolarization of SA node cells, ultimately influencing heart rate in patients with dilated cardiomyopathy. Based on this mechanism of action Amgen's CORLANOR is US FDA-approved for treating stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients aged 6 months to 18 years old.

Learn more about the FDA-approved drugs for Dilated Cardiomyopathy @ Drugs for Dilated Cardiomyopathy Treatment- https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Dilated Cardiomyopathy Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Dilated Cardiomyopathy Companies- Pfizer, Capricor Therapeutics, MyoKardia, Cumberland Pharmaceuticals, Berlin Cures, and others.
• Dilated Cardiomyopathy Pipeline Therapies- Danicamtiv, Ixmyelocel, ARRY-371797, Ifetroban, BC 007, and others.
• Dilated Cardiomyopathy Market Dynamics: Dilated Cardiomyopathy Market Drivers and Barriers
• Dilated Cardiomyopathy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Dilated Cardiomyopathy Drugs in development @ Dilated Cardiomyopathy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Dilated Cardiomyopathy Market Report Introduction
3. Dilated Cardiomyopathy Market Overview at a Glance
4. Dilated Cardiomyopathy Epidemiology and Market Forecast Methodology
5. Dilated Cardiomyopathy Executive Summary
6. Key Dilated Cardiomyopathy Events
7. Dilated Cardiomyopathy Disease Background and Overview
8. Dilated Cardiomyopathy Patient Journey
9. Dilated Cardiomyopathy Epidemiology and Patient Population
10. Dilated Cardiomyopathy Marketed Drugs
11. Dilated Cardiomyopathy Emerging Drugs
12. Dilated Cardiomyopathy: Market Analysis
13. Key Opinion Leaders' Views
14. Dilated Cardiomyopathy SWOT Analysis
15. Dilated Cardiomyopathy Unmet Needs
16. Dilated Cardiomyopathy Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Psoriasis Vulgaris Market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Immune Checkpoints Activators Market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Diabetic Wound Market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Overactive Bladder Syndrome Market- https://www.delveinsight.com/report-store/underactive-bladder-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.